Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

JW Pharmaceutical’s Gout Drug Candidate Outperforms Febuxostat in Phase 3 Trial

JW Pharmaceutical has reported positive results from a multinational Phase 3 trial of its gout drug candidate epaminurad (code name URC102), with the 6mg dose demonstrating statistically superior…

  • JW Pharmaceutical's epaminurad (URC102) outperformed febuxostat in Phase 3 gout trial.
  • Epaminurad achieved 50.0% serum uric acid reduction vs. 38.3% for febuxostat 40mg.
  • Safety profiles were comparable with no drug-related deaths reported.

Celltrion Expands Market Presence in Spain and Portugal Through Tender Wins

Celltrion is rapidly strengthening its presence in Spain and Portugal, securing a series of government and regional tenders while expanding sales and marketing activities to drive prescriptions and…

  • Celltrion wins government tenders in Spain and Portugal, expanding market presence.
  • Omlyclo biosimilar dominates Spanish market with 90% share by June.
  • Actemra and other biosimilars gain significant market share in Spain and Portugal.

More from Wednesday 12 August →